I, Dr. Babu Gajendran, working as a Research Scientist in the State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China. My area of interest is the development of chemotherapeutic drugs from natural plant and animal sources to contribute a better treatment to cancer patients especially, leukemic patients. My interest even extends to explore the cellular signaling of the drug-treated models, both in vitro as well as in vivo in the field of Molecular Cancer Biology. My research includes the pre-clinical trials connecting the methodologies in chemistry as well as biology. Recently our research team discovered a C21-steroidal derivative called A671, 3-O-chloroacetyl-gagamine, suppresses the growth of T-cell lymphoma in mice. A671 activates SAP18 to suppress the transcription of SIRT3, inhibiting cell growth. This study presents a new pharmacological target pathway for T-cell lymphoma. Moreover, I work on tumor microenvironment in the erythro-leukemogenesis. The work focuses mainly on cancer immunotherapy, especially EPO induces anti-leukemia activity by activating specific immune cells within tumor microenvironment, leading to leukemic inhibition. With this regard, I have a patent for my credit. I am a regional director in the Society of Chemical and Synthetic Biology (SCSB). A portion of my research work has been highlighted in NATURE INDIA by Nature Publishing Group.